Progression Markers for Cognitive Impairment in Parkinson's Disease Dementia (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications that propose to identify biomarkers for onset and progression of cognitive impairment in Parkinson’s Disease (PD) through Parkinson's Disease Dementia (PDD).  The use of well-characterized populations of PD and PDD patients that have been, and can continue to be, followed longitudinally with clinical assessments and biospecimen collection to autopsy should be considered.   


  • R01 Due Dates: Feb. 5, Jun. 5, Oct. 5
  • AIDS Application Due Dates: Jan. 7, May 7, Sep. 7

PAS-19-210 Expiration Date May 08, 2022




Environmental & Life Sciences
Medical - Basic Science

External Deadline

February 5, 2022